We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Texas-based clinical-stage company Bellicum Pharmaceuticals has taken a massive stock hit after the FDA put a hold on its trials of its T-cell therapy BPX-501 due to three cases of encephalopathy in participants that are thought to be treatment-related.
Several former National Hockey League players have joined the growing number of pro athletes who have pledged their brains to research on chronic traumatic encephalopathy (CTE) -- a devastating brain disease that has been linked to repetitive head trauma.